ReviewDrug discovery today2022
Artificial intelligence for the discovery of novel antimicrobial agents for emerging infectious diseases.
Review in Drug discovery today, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 46 citations in OpenAlex.
- Full-Body AI Agent: A Perspective on Multi-Scale Collaborative AI for Systemic Biology and Precision Medicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- A multimodal human protein embeddings database: DeepDrug Protein Embeddings Bank (DPEB).NAR genomics and bioinformatics · 2026Article
- Framework for evaluating explainable AI in antimicrobial drug discovery.Journal of cheminformatics · 2026Article
- AI-Powered Microscopic Diagnostic Techniques forJournal of dentistry (Shiraz, Iran) · 2026Article
- Role of Artificial Intelligence in Infectious Diseases and Antimicrobial Resistance: A Comprehensive Review on Diagnostic, Treatment, and Prevention Aspects.Saudi medical journal · 2026Review
- Beyond the hype: navigating the real-world applications of artificial intelligence (AI) in healthcare.Medical review (2021) · 2026Review
- Machine learning models for drug-drug interaction prediction from computational discovery to clinical application.NPJ digital medicine · 2026Review
- The emerging threat of Oropouche virus in Latin America: epidemiology, clinical manifestations, diagnosis, and management.Annals of medicine and surgery (2012) · 2025Review
- Review
- A Multi-Layered Framework for Modeling Human Biology: From Basic AI Agents to a Full-Body AI Agent.ArXiv · 2025Article
- Role of artificial intelligence in advancing immunology.Immunologic research · 2025Review
- The role of artificial intelligence and machine learning in predicting and combating antimicrobial resistance.Computational and structural biotechnology journal · 2025Review
- Artificial Intelligence (AI) Applications in Drug Discovery and Drug Delivery: Revolutionizing Personalized Medicine.Pharmaceutics · 2024Review
- A Chronicle Review ofIndian journal of microbiology · 2024Review
- Emerging Microorganisms and Infectious Diseases: One Health Approach for Health Shared Vision.Genes · 2024Review
- Generative artificial intelligence in drug discovery: basic framework, recent advances, challenges, and opportunities.Frontiers in pharmacology · 2024Review
- Identification of oral therapeutics using an AI platform against the virus responsible for COVID-19, SARS-CoV-2.Frontiers in pharmacology · 2023Article
- Ganoderma microsporum immunomodulatory protein acts as a multifunctional broad-spectrum antiviral against SARS-CoV-2 by interfering virus binding to the host cells and spike-mediated cell fusion.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Article
- Feasibility and application of machine learning enabled fast screening of poly-beta-amino-esters for cartilage therapies.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The search for effective drugs to treat new and existing diseases is a laborious one requiring a large investment of capital, resources, and time. The coronavirus 2019 (COVID-19) pandemic has been a painful reminder of the lack of development of new antimicrobial agents to treat emerging infectious diseases. Artificial intelligence (AI) and other in silico techniques can drive a more efficient, cost-friendly approach to drug discovery by helping move potential candidates with better clinical tolerance forward in the pipeline. Several research teams have developed successful AI platforms for hit identification, lead generation, and lead optimization. In this review, we investigate the technologies at the forefront of spearheading an AI revolution in drug discovery and pharmaceutical sciences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.